{
 "id": "epjvgdvhzc",
 "slug": "machine-perfusion",
 "title": "Machine perfusion",
 "updated": "2026-10-15",
 "topic_path": [
  {
   "id": "life",
   "label": "Life and health",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life"
  },
  {
   "id": "life.health",
   "label": "Human health and medicine",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health"
  },
  {
   "id": "life.health.clinical",
   "label": "Clinical assessment and procedures",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical"
  },
  {
   "id": "life.health.clinical.clinical-transplantation",
   "label": "Organ and tissue transplantation",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-transplantation"
  },
  {
   "id": "life.health.clinical.clinical-transplantation.alpha-li-to-x",
   "label": "Titles Li to X",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-transplantation.alpha-li-to-x"
  }
 ],
 "geo": [
  {
   "id": "geo.nongeo.t1946.life.health.clinical.clinical-transplantation",
   "label": "Non-geographic · 1946 to 2000: Organ and tissue transplantation",
   "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-transplantation",
   "path": [
    {
     "id": "geo.nongeo",
     "label": "Non-geographic",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo"
    },
    {
     "id": "geo.nongeo.t1946",
     "label": "Non-geographic · 1946 to 2000",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946"
    },
    {
     "id": "geo.nongeo.t1946.life",
     "label": "Life and health",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life"
    },
    {
     "id": "geo.nongeo.t1946.life.health",
     "label": "Human health and medicine",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health"
    },
    {
     "id": "geo.nongeo.t1946.life.health.clinical",
     "label": "Clinical assessment and procedures",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical"
    },
    {
     "id": "geo.nongeo.t1946.life.health.clinical.clinical-transplantation",
     "label": "Organ and tissue transplantation",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-transplantation"
    }
   ]
  }
 ],
 "excerpt": "Machine perfusion is a transplantation technique that circulates oxygenated fluid through a donor organ between retrieval and implantation, reducing injury compared with static cold storage on ice.",
 "snippet": "Machine perfusion is a transplantation technique that circulates oxygenated fluid through a donor organ between retrieval and implantation, reducing injury compared with static cold storage on ice.",
 "node": "life.health.clinical.clinical-transplantation.alpha-li-to-x",
 "markdown": "# Machine perfusion\n\nMachine perfusion is a transplantation medicine technique that dynamically circulates perfusate (fluid pumped through the organ to preserve it) through a donor organ, with oxygenation and temperature depending on the technique; it is usually performed outside the body as an alternative or adjunct to static cold storage on ice between retrieval and implantation, although in-situ normothermic regional perfusion is performed within the donor. Static cooling slows metabolism but leaves the organ anoxic; in the cited randomized trial of controlled donation after circulatory death (DCD) kidneys, delayed graft function (DGF, the need for dialysis after transplantation) occurred in 58.5% of kidneys with static cold storage and 60.7% of kidneys with static cold storage plus 1 hour of normothermic perfusion.<sup>[1](https://www.nature.com/articles/s41591-023-02376-7)</sup> By circulating the organ, perfusion delivers oxygen and nutrients, and in warmer regimes allows the organ to be functionally tested before implantation.<sup>[1](https://www.nature.com/articles/s41591-023-02376-7)</sup><sup> • </sup><sup>[2](https://www.ovid.com/jnls/transplantjournal/fulltext/10.1097/tp.0000000000003817~renal-normothermic-machine-perfusion-the-road-toward)</sup> Renal hypothermic perfusion is standard of care in many countries, and nearly 1 in 5 livers in the United States now undergoes normothermic perfusion.<sup>[3](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2025.1642724/full)</sup>\n\n| Key fact | Detail |\n|---|---|\n| Temperature regimes | Hypothermic machine perfusion (HMP) below 12 °C, normothermic (NMP) above 35 °C, with oxygenated (HOPE), rewarming (COR), and in-situ regional (NRP) variants<sup>[4](https://karger.com/vis/article/38/4/243/827281/Machine-Perfusion-in-Liver-Transplantation-A)</sup> |\n| Kidney evidence | HMP reduces DGF versus static cold storage (RR 0.78, 95% CI 0.69–0.88, high certainty) and improves one-year graft survival (HR 0.46, 95% CI 0.29–0.75)<sup>[5](https://pubmed.ncbi.nlm.nih.gov/38979743/)</sup> |\n| Liver DCD evidence | Dual hypothermic oxygenated perfusion cut nonanastomotic biliary strictures from 18% to 6% (RR 0.36)<sup>[6](https://www.nejm.org/doi/full/10.1056/NEJMoa2031532)</sup> |\n| Economics | Machine perfusion was $2,726 cheaper per kidney transplant at 12 months ($8,668 vs $11,394), despite higher device costs<sup>[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC11200710/)</sup> |\n| Heart evidence | Hypothermic oxygenated perfusion of donor hearts reduced primary graft dysfunction from 28% to 11% (RR 0.39)<sup>[8](https://lirias.kuleuven.be/4177323?limo=0)</sup> |\n| Adoption | Renal HMP is standard of care in many countries; nearly 1 in 5 US livers undergoes NMP<sup>[3](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2025.1642724/full)</sup> |\n\n## How it works\n\nStatic cold storage cools the organ to ice temperature, reducing cellular metabolism to about 5% of the physiological rate in one trial account, although reviews place the residual rate nearer 10%.<sup>[1](https://www.nature.com/articles/s41591-023-02376-7)</sup><sup> • </sup><sup>[3](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2025.1642724/full)</sup> Even at this reduced rate the organ is anoxic: mitochondria accumulate succinate, which at reperfusion is rapidly metabolized, driving superoxide generation by reversed electron transport and the reactive oxygen species that cause ischemia-reperfusion injury.<sup>[3](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2025.1642724/full)</sup> Chouchani and colleagues showed this process can be abrogated even under hypothermic conditions by providing oxygen, the mechanism exploited in hypothermic oxygenated perfusion (HOPE).<sup>[3](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2025.1642724/full)</sup> Hypothermic grafts still consume oxygen at 5–10% of the in-situ rate, which motivates active oxygenation even at 4 °C.<sup>[9](https://link.springer.com/article/10.1007/s10353-025-00856-3)</sup> Normothermic perfusion at 36–38 °C with oxygenated, blood-based perfusate restores near-complete metabolism, replenishes ATP, and makes the organ functionally testable before implantation.<sup>[10](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2026.1892796/full)</sup> [Perfusion](https://www.edgepedia.org/perfusion) also produces measurements: flows, pressures, vascular resistance, perfusate lactate, pH, and, in warm liver perfusion, bile production.\n\n## How it is done\n\nAfter retrieval, the organ's inflow vessels are cannulated; in hypothermic perfusion the outflow vessels are generally left open, because cannulating them can raise outflow resistance and cause organ swelling and interstitial edema.<sup>[11](https://cryoletters.org/documents/perspectives/perspective-43-5-255-263-cherkashina.pdf)</sup> Optimized hypothermic flow rates are about 25% of what the organ would receive in the body, reflecting depressed metabolism and differing perfusate viscosity.<sup>[11](https://cryoletters.org/documents/perspectives/perspective-43-5-255-263-cherkashina.pdf)</sup> For kidneys, a pulsatile renal artery pressure of 25–30 mmHg appears ideal.<sup>[9](https://link.springer.com/article/10.1007/s10353-025-00856-3)</sup> In the Dutch DHOPE-DCD liver protocol, the Liver Assist device perfuses at 10 °C with Belzer solution through both portal vein and hepatic artery at 5 mmHg and 25 mmHg respectively, oxygenated with 500 ml/min of 100% oxygen for at least 2 hours.<sup>[6](https://www.nejm.org/doi/full/10.1056/NEJMoa2031532)</sup> Normothermic perfusion uses blood-based perfusate, an oxygenator, heater, and pump; one extended protocol targets 25–30 ml/100 g/min arterial and 75–80 ml/100 g/min portal flow, warming from 25 °C to 37 °C within 30 minutes.<sup>[12](https://www.nature.com/articles/s43856-024-00636-2)</sup> Chinese national guidelines specify perfusate pH 7.35–7.45 and pO2 200–300 mmHg for renal NMP.<sup>[13](https://zhyzzz.cma-cmc.com.cn/EN/Y2025/V19/I05/308)</sup> In situ normothermic regional perfusion (NRP) during DCD retrieval establishes an abdominal ECMO circuit at 37 °C for typically 2 hours, started only after the thoracic aorta is cross-clamped and vented, primed with 1.5 L of Hartmann's solution plus 4 units of red cells, and run at 2–3 L/min with a starting FiO2 of 21%.<sup>[14](https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/36508/uk-protocol-for-normothermic-regional-perfusion-version-114-final.pdf)</sup>\n\n## Origin\n\nDevices for circulating oxygenated fluid through isolated organs have been described, and by the late 1960s a clinically applicable hypothermic perfusion device was in use, with a human kidney preserved by machine perfusion for 17 hours successfully transplanted.<sup>[15](https://lirias.kuleuven.be/retrieve/529f7294-2738-49a7-96e5-ae6b7e8949c3)</sup><sup> • </sup><sup>[16](https://mdpi-res.com/d_attachment/jcm/jcm-12-03207/article_deploy/jcm-12-03207-v3.pdf?version=1683622938)</sup> The modern evidence base began when Cyril Moers and colleagues reported the Eurotransplant MP-Trial in the New England Journal of Medicine in 2008, a randomized comparison of non-oxygenated HMP with cold storage in 336 kidney pairs in which DGF occurred in 20.8% versus 26.5% and one-year graft survival was 94% versus 90%.<sup>[17](https://doi.org/10.1056/nejmoa0802289)</sup> Clinical kidney NMP was performed using an extended-criteria-donor kidney rejected by five other UK centers.<sup>[18](https://www.mdpi.com/2673-3943/2/4/44)</sup> A human liver NMP series followed in 2016, establishing safety and feasibility.<sup>[10](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2026.1892796/full)</sup> David Nasralla and colleagues published the pivotal randomized trial of normothermic liver preservation in Nature in 2018,<sup>[19](https://doi.org/10.1038/s41586-018-0047-9)</sup> and Ina Jochmans and colleagues reported the COMPARE phase 3 trial of oxygenated versus standard cold kidney perfusion in [The Lancet](https://www.edgepedia.org/the-lancet) in 2020.<sup>[20](https://doi.org/10.1016/s0140-6736%2820%2932411-9)</sup>\n\n## Variants\n\nCurrent nomenclature distinguishes HMP (cold, no oxygen), HOPE (cold with oxygen), controlled oxygenated rewarming (COR, progressive transition from hypothermia to normothermia), NMP (warm, oxygenated, usually blood-based perfusate), and NRP (in-situ perfusion after circulatory death).<sup>[3](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2025.1642724/full)</sup> Standardized cutoffs place NMP above 35 °C and HMP below 12 °C.<sup>[4](https://karger.com/vis/article/38/4/243/827281/Machine-Perfusion-in-Liver-Transplantation-A)</sup> HOPE is typically applied end-ischemic at 4–8 °C through the portal vein alone or with the hepatic artery added (D-HOPE).<sup>[21](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2026.16100/full)</sup> Commercial kidney HMP devices include LifePort, Kidney Assist, RM3, WAVES, and VitaSmart.<sup>[16](https://mdpi-res.com/d_attachment/jcm/jcm-12-03207/article_deploy/jcm-12-03207-v3.pdf?version=1683622938)</sup> For livers, the OrganOx metra is an FDA-approved transportable NMP system intended for normothermic perfusion of donor transplant livers for up to 24 hours,<sup>[22](https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200035D.pdf)</sup> alongside the Liver Assist device. The TransMedics OCS is the only ex vivo heart perfusion platform using warm, oxygenated, nutrient-enriched donor blood, and OCS and XVIVO devices serve lung ex vivo lung perfusion (EVLP).<sup>[23](https://pmc.ncbi.nlm.nih.gov/articles/PMC11075812/)</sup>\n\n## Applications\n\n**Kidney.** HMP is the most established modality and is standard of care in many countries; HOPE is becoming the clinical standard for kidney preservation in the Netherlands.<sup>[3](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2025.1642724/full)</sup><sup> • </sup><sup>[24](https://www.mdpi.com/2077-0383/15/6/2287)</sup> A 2024 Cochrane review of 22 studies found non-oxygenated HMP reduces DGF (RR 0.78, high certainty) and improves one-year graft survival (HR 0.46).<sup>[5](https://pubmed.ncbi.nlm.nih.gov/38979743/)</sup> **Liver.** DHOPE reduces biliary complications in DCD grafts,<sup>[6](https://www.nejm.org/doi/full/10.1056/NEJMoa2031532)</sup> NMP enables viability testing and rescue of declined livers, and extended NMP has sustained human livers for a median of 168 hours experimentally.<sup>[12](https://www.nature.com/articles/s43856-024-00636-2)</sup> The pivotal European trial showed 50% lower peak AST, a 50% lower discard rate, and non-utilization of 11.7% versus 24.1% with cold storage.<sup>[19](https://doi.org/10.1038/s41586-018-0047-9)</sup><sup> • </sup><sup>[25](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2026.16653/full)</sup> **Heart.** In a 229-patient multinational trial (2020–2023), all 100 hearts preserved with HOPE were transplantable, and PGD fell from 28% to 11%.<sup>[8](https://lirias.kuleuven.be/4177323?limo=0)</sup> **Lung.** EVLP protocols range from the Lund protocol (2–7 hours) to Toronto (up to 12 hours) and the Hannover OCS protocol (up to 10 hours); in the 2019 EXPAND trial, 87% of OCS-preserved lungs were transplanted with 99% 30-day survival.<sup>[23](https://pmc.ncbi.nlm.nih.gov/articles/PMC11075812/)</sup> **Viability assessment.** For kidneys, the Hosgood Quality Assessment Score combines perfusion parameters, macroscopic appearance, and urine output, but a recent randomized trial found no correlation with DGF.<sup>[26](https://www.ovid.com/journals/artorg/fulltext/10.1111/aor.70080~optimizing-prolonged-6h-normothermic-machine-perfusion-of)</sup> For livers, the [Birmingham](https://www.edgepedia.org/birmingham) criteria after 3 hours of NMP require lactate ≤2.5 mmol/L or active bile production plus at least two of perfusate pH ≥7.30, hepatic artery flow ≥150 mL/min with portal vein flow ≥500 mL/min, and homogeneous appearance; the VITTAL trial applying expanded criteria achieved a 71% liver rescue rate with 100% survival at 3 months.<sup>[10](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2026.1892796/full)</sup> In UK NRP practice, livers are accepted with an ALT rise ≤500 iu/L over 2 hours.<sup>[14](https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/36508/uk-protocol-for-normothermic-regional-perfusion-version-114-final.pdf)</sup> Emerging biomarkers include perfusate flavin mononucleotide (FMN), a mitochondrial damage marker now under international validation.<sup>[10](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2026.1892796/full)</sup>\n\n## Limitations and alternatives\n\nNMP systems carry higher complexity and cost, and pump failure during normothermic perfusion risks losing the organ, whereas HMP is simpler, cheaper, and carries minimal pump-failure risk.<sup>[3](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2025.1642724/full)</sup> Documented failure modes include hemolysis, reduced by using red cells stored 7 days or less,<sup>[26](https://www.ovid.com/journals/artorg/fulltext/10.1111/aor.70080~optimizing-prolonged-6h-normothermic-machine-perfusion-of)</sup> arterial cannulation failure, which prevented NMP in 8.2% of randomized kidneys in one trial,<sup>[1](https://www.nature.com/articles/s41591-023-02376-7)</sup> and edema from outflow cannulation in hypothermic circuits.<sup>[11](https://cryoletters.org/documents/perspectives/perspective-43-5-255-263-cherkashina.pdf)</sup> Cost-effectiveness varies widely: UK modeling priced HOPE at £204,059 per QALY, outside the £30,000 threshold, while liver NMP was costed at £8,300 per QALY in one analysis and over £1,000,000 per QALY in another.<sup>[3](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2025.1642724/full)</sup> Economic analyses nonetheless find HMP cost-saving in US and European settings.<sup>[5](https://pubmed.ncbi.nlm.nih.gov/38979743/)</sup> No perfusion platform is approved for use beyond 24 hours.<sup>[21](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2026.16100/full)</sup> The benefit is bounded by negative trials: end-ischemic NMP of 1 hour did not reduce DGF (60.7% versus 58.5%) and was inferior to continuous HMP in an indirect comparison (indirect HR 0.31), and end-ischemic oxygenated HMP (median 4.6 hours) showed no benefit over cold storage.<sup>[1](https://www.nature.com/articles/s41591-023-02376-7)</sup><sup> • </sup><sup>[5](https://pubmed.ncbi.nlm.nih.gov/38979743/)</sup> The COMPARE trial found no significant difference in its primary eGFR outcome, with lower graft failure (3% versus 10%) only under sensitivity analysis.<sup>[20](https://doi.org/10.1016/s0140-6736%2820%2932411-9)</sup><sup> • </sup><sup>[18](https://www.mdpi.com/2673-3943/2/4/44)</sup> Alternatives include supercooling, which Tim A. Berendsen and colleagues showed in [Nature Medicine](https://www.edgepedia.org/nature-medicine) in 2014 enabled survival after 4 days of liver preservation,<sup>[27](https://doi.org/10.1038/nm.3588)</sup> and controlled oxygenated rewarming of cold-stored kidneys, shown in 2015 to improve creatinine clearance and reduce apoptotic signaling.<sup>[18](https://www.mdpi.com/2673-3943/2/4/44)</sup>\n\n## References\n\n1. [Normothermic machine perfusion versus static cold storage in donation after circulatory death kidney transplantation: a randomized controlled trial (Nature Medicine)](https://www.nature.com/articles/s41591-023-02376-7)\n2. [Renal Normothermic Machine Perfusion: The Road Toward Clinical Implementation (Transplantation)](https://www.ovid.com/jnls/transplantjournal/fulltext/10.1097/tp.0000000000003817~renal-normothermic-machine-perfusion-the-road-toward)\n3. [The Hitchhiker's guide to isolated organ perfusion: a journey to 2040 (Frontiers in Transplantation, 2025)](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2025.1642724/full)\n4. [Machine Perfusion in Liver Transplantation: A Systematic Review and Meta-Analysis (Visceral Medicine)](https://karger.com/vis/article/38/4/243/827281/Machine-Perfusion-in-Liver-Transplantation-A)\n5. [Normothermic and hypothermic machine perfusion preservation versus static cold storage for deceased donor kidney transplantation (Cochrane systematic review, updated June 2024)](https://pubmed.ncbi.nlm.nih.gov/38979743/)\n6. [Hypothermic Machine Perfusion in Liver Transplantation, A Randomized Trial (DHOPE-DCD, NEJM)](https://www.nejm.org/doi/full/10.1056/NEJMoa2031532)\n7. [Perfusion Techniques in Kidney Allograft Preservation to Reduce Ischemic Reperfusion Injury: A Systematic Review and Meta-Analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC11200710/)\n8. [Hypothermic oxygenated perfusion of the donor heart in heart transplantation: randomised, controlled, open-label, multicentre clinical trial (Lancet, via KU Leuven repository)](https://lirias.kuleuven.be/4177323?limo=0)\n9. [Normothermic Machine Perfusion of Kidney Grafts: Devices, Endpoints, and Clinical Implementation (European Surgery, Springer)](https://link.springer.com/article/10.1007/s10353-025-00856-3)\n10. [Graft quality assessment during machine perfusion in liver transplantation: a review of current evidence and emerging strategies (Frontiers in Transplantation, 2026)](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2026.1892796/full)\n11. [Hypothermic organ perfusion in the 2020s: mixing the benefits of low temperatures and dynamic flow outside the body (CryoLetters)](https://cryoletters.org/documents/perspectives/perspective-43-5-255-263-cherkashina.pdf)\n12. [A reproducible extended ex-vivo normothermic machine liver perfusion protocol utilising improved nutrition and targeted vascular flows (Communications Medicine)](https://www.nature.com/articles/s43856-024-00636-2)\n13. [Operational guidelines for renal normothermic machine perfusion (Chinese Journal of Transplantation)](https://zhyzzz.cma-cmc.com.cn/EN/Y2025/V19/I05/308)\n14. [UK Protocol for Normothermic Regional Perfusion (NRP) in controlled Donation after Circulatory determination of Death (NHS Blood and Transplant)](https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/36508/uk-protocol-for-normothermic-regional-perfusion-version-114-final.pdf)\n15. [Hypothermic machine perfusion of kidneys retrieved from standard and high risk donors (Transplant International, accepted version)](https://lirias.kuleuven.be/retrieve/529f7294-2738-49a7-96e5-ae6b7e8949c3)\n16. [Current Evidence and Future Perspectives to Implement Continuous and End-Ischemic Use of Normothermic and Oxygenated Hypothermic Machine Perfusion in Clinical Practice (J Clin Med 2023; merged with PMC10178893 copy)](https://mdpi-res.com/d_attachment/jcm/jcm-12-03207/article_deploy/jcm-12-03207-v3.pdf?version=1683622938)\n17. [Cyril Moers and colleagues (2008). Machine Perfusion or Cold Storage in Deceased-Donor Kidney Transplantation. New England Journal of Medicine.](https://doi.org/10.1056/nejmoa0802289)\n18. [Advances in Hypothermic and Normothermic Perfusion in Kidney Transplantation (MDPI Transplantology)](https://www.mdpi.com/2673-3943/2/4/44)\n19. [David Nasralla and colleagues (2018). A randomized trial of normothermic preservation in liver transplantation. Nature.](https://doi.org/10.1038/s41586-018-0047-9)\n20. [Oxygenated versus standard cold perfusion preservation in kidney transplantation (COMPARE): a randomised, double-blind, paired, phase 3 trial (The Lancet, 2020)](https://doi.org/10.1016/s0140-6736%2820%2932411-9)\n21. [Time as a Therapeutic Ally: The Promise of Long-Term Solid Organ and Tissue Perfusion (Transplant International, 2026)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2026.16100/full)\n22. [OrganOx metra US Patient Brochure (FDA P200035)](https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200035D.pdf)\n23. [Ex vivo lung perfusion and the Organ Care System: a review](https://pmc.ncbi.nlm.nih.gov/articles/PMC11075812/)\n24. [Comparison of Normothermic and Subnormothermic Machine Perfusion of Porcine Kidneys Using a Fully Synthetic Perfusion Solution: A Proof-of-Concept Study (J Clin Med, 2026)](https://www.mdpi.com/2077-0383/15/6/2287)\n25. [The perfused liver utilisation study (PLUS): challenges and innovation in the evaluation of an emerging technology (Transplant International, 2026)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2026.16653/full)\n26. [Optimizing Prolonged (6 h) Normothermic Machine Perfusion of Donor Kidneys (Artificial Organs)](https://www.ovid.com/journals/artorg/fulltext/10.1111/aor.70080~optimizing-prolonged-6h-normothermic-machine-perfusion-of)\n27. [Tim A Berendsen and colleagues (2014). Supercooling enables long-term transplantation survival following 4 days of liver preservation. Nature Medicine.](https://doi.org/10.1038/nm.3588)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Clinical assessment and procedures › Organ and tissue transplantation › Titles Li to X*\n\n*Initially written Sep 29, 2026 · Edited: Oct 15, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n",
 "same_as": [],
 "url": "https://www.edgepedia.org/machine-perfusion",
 "markdown_url": "https://www.edgepedia.org/machine-perfusion.md",
 "license": {
  "name": "Edgepedia Community License 1.0",
  "url": "https://www.edgepedia.org/edgepedia/license",
  "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.",
  "spdx": "LicenseRef-Edgepedia-Community-1.0"
 },
 "credit": "\"Machine perfusion\", Edgepedia (EdgeChat), https://www.edgepedia.org/machine-perfusion. Edgepedia Community License 1.0.",
 "credit_md": "\"[Machine perfusion](https://www.edgepedia.org/machine-perfusion)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/machine-perfusion](https://www.edgepedia.org/machine-perfusion). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).",
 "credit_html": "\"<a href=\"https://www.edgepedia.org/machine-perfusion\">Machine perfusion</a>\", Edgepedia (EdgeChat), <a href=\"https://www.edgepedia.org/machine-perfusion\">https://www.edgepedia.org/machine-perfusion</a>. <a href=\"https://www.edgepedia.org/edgepedia/license\">Edgepedia Community License 1.0</a>.",
 "speakable": "Machine perfusion is a transplantation technique that circulates oxygenated fluid through a donor organ between retrieval and implantation, reducing injury compared with static cold storage on ice."
}
